Ticagrelor
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sickle Cell Disease
Conditions
Sickle Cell Disease
Trial Timeline
Mar 28, 2018 → May 7, 2019
NCT ID
NCT03492931About Ticagrelor
Ticagrelor is a phase 1 stage product being developed by AstraZeneca for Sickle Cell Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03492931. Target conditions include Sickle Cell Disease.
What happened to similar drugs?
3 of 20 similar drugs in Sickle Cell Disease were approved
Approved (3) Terminated (10) Active (8)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03492931 | Phase 1 | Completed |
| NCT03145194 | Phase 2 | UNKNOWN |
| NCT02341729 | Approved | Completed |
| NCT02292277 | Pre-clinical | Completed |
| NCT02282332 | Approved | Completed |
| NCT02071212 | Phase 2 | Completed |
| NCT01870921 | Approved | Completed |
Competing Products
20 competing products in Sickle Cell Disease